今年首个！又一重组蛋白企业要上市了

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has submitted its IPO registration application and is expected to become the first successful listed recombinant protein company this year [1][2]. Group 1: Company Overview - Heyuan Biotechnology focuses on plant-based recombinant protein expression technology, specifically developing recombinant human serum albumin using rice endosperm cell bioreactor systems [4][12]. - The company was founded in 2006 and has a leading global plant bioreactor technology platform, with its founder being a professor at Wuhan University [8]. Group 2: Financial Performance - The company has reported continuous losses, with revenues of 13.40 million yuan, 24.26 million yuan, and 25.22 million yuan for 2022, 2023, and 2024 respectively, and net losses of -144 million yuan, -187 million yuan, and -151 million yuan for the same years [9][10]. - As of the end of 2024, the cumulative unabsorbed losses reached 851 million yuan [9]. Group 3: Product Development and Market Potential - Heyuan Biotechnology's lead product, recombinant human serum albumin injection (HY1001), is expected to be approved for market soon, which could reduce reliance on imported products in China [11]. - The company has established a pilot-scale production capacity and is building a commercial-scale production line with an annual output of 10 tons of OsrHSA raw liquid and formulations [12]. - A strategic cooperation framework has been signed to establish a production line with an annual capacity of 20 tons in Western China [12][13]. Group 4: Technological Advancements - The company has achieved a breakthrough in its "rice-based blood production" technology, which has garnered significant attention in the capital market [7]. - The rice expression system can yield 15-20 grams of protein per kilogram of brown rice, providing advantages in high yield, simple processes, low costs, and scalability [12].